查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1454070

到 2030 年自动注射器市场预测：按类型、治疗、给药途径、技术、最终用户和地区进行的全球分析

Autoinjectors Market Forecasts to 2030 - Global Analysis By Type (Reusable, Disposable, Customized, Prefilled and Other Types), Therapy, Route of Administration, Technology, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球自动注射器市场规模将达到 1,111 亿美元，预计到 2030 年将达到 2,646 亿美元，预测期内复合年增长率为 13.2%。

自动注射器是医疗设备，设计用于在紧急情况下注射单一剂量的特定药物，例如严重过敏反应（过敏反应）或其他医疗紧急情况。该设备结构紧凑、便携且易于使用，使个人能够快速、轻鬆地自行给药。这些设备通常用于输送治疗过敏反应的肾上腺素、军事用的神经毒剂解毒剂或治疗多发性硬化症和类风湿性关节炎等慢性疾病的药物。在急诊医学领域，我们在时间紧迫的情况下快速提供救命药物方面发挥着重要作用。

根据美国国家健康调查 (NHIS)，近 52% 的美国成年人被诊断出患有至少一种慢性病，包括气喘、糖尿病和高血压。

慢性病增加

类风湿性关节炎、多发性硬化症和糖尿病等疾病在世界各地变得越来越普遍，增加了对方便且高效的药物输送系统的需求。自动注射器为患者提供了一个易于使用的自我给药解决方案，并有助于其在慢性病管理中的日益普及。这一趋势凸显了医疗保健领域创新和可近性的重要性，以满足慢性疾病患者不断变化的需求。

严格的监管要求

满足严格的监管要求是在该市场运营的公司面临的主要挑战。这些要求包括安全性、功效、品管和製造标准等各个方面。在产品的整个生命週期中，需要进行广泛的测试、记录并遵守严格的准则，以确保符合监管机构制定的法规。违规可能导致产品核可延迟、代价高昂的召回以及公司声誉受损。

过敏反应和严重过敏反应迅速增加

自动注射器市场的过敏反应和严重过敏反应显着增加。这一增长凸显了对可靠、高效的紧急治疗提供机制的迫切需求。在这些紧急情况下，自动注射器在快速、准确地施用救生药物方面发挥关键作用。随着意识的增强和越来越多的人需要使用此类设备，市场对改进技术和创新的需求不断增长，以满足这种紧迫的医疗需求。

自动注射器高成本

自动注射器的高价格仍然是市场的主要挑战。这些设备对于治疗严重过敏反应的肾上腺素等药物至关重要，但它们的价格往往过高，给患者和医疗保健系统带来了经济负担。儘管有潜在的挽救生命的作用，但高价格限制了可及性，并导致人们对公平医疗保健的担忧。解决这一问题的努力包括倡导学名药替代品和提高定价透明度以减轻患者的经济负担。

COVID-19 的影响：

COVID-19 大流行对自动注射器市场产生了重大影响。最初，供应链中断导致製造和分销短缺和延误。然而，随着疫情的发展，由于人们越来越关注自我给药和远距医疗的需求，对自动注射器的需求激增。因此，在疫情的挑战下，自动注射器市场因慢性病增加和对家庭医疗保健解决方案的偏好等因素而扩大。

抛弃式部分在预测期内将是最大的

预计抛弃式市场在预测期内将是最大的市场。这些设备易于使用，降低针刺伤害的风险，并提高患者的依从性和安全性。慢性病盛行率上升和生技药品使用范围扩大等因素正在推动市场扩张。此外，技术进步和产品创新也促进了市场的成长。

预计糖尿病产业在预测期内复合年增长率最高

由于全球糖尿病盛行率不断上升以及自我管理技术的进步，预计糖尿病产业在预测期内将出现最高的复合年增长率。自动注射器提供胰岛素注射的便利性和准确性，并提高患者的依从性。此外，旨在提高设备功效和患者体验的研发投资预计将推动主要产业参与者之间的创新和竞争，从而维持市场势头。

比最大的地区

由于糖尿病和类风湿性关节炎等慢性病的盛行率不断上升，预计北美在预测期内将占据最大的市场占有率。此外，自我给药设备的日益普及和给药系统的技术进步正在推动市场扩张。此外，有利的政府倡议和报销政策正在支持全部区域自动注射器的普及并促进市场开拓。

复合年增长率最高的地区：

预计亚太地区在预测期内将维持最高的复合年增长率。该地区糖尿病、类风湿性关节炎、多发性硬化症和过敏反应等慢性病的盛行率正在增加。亚太地区各国监管机构越来越注重确保包括自动注射器在内的医疗设备的安全性和有效性。每个国家的人口老化正在推动对自动注射器的需求，因为老年人经常患有慢性疾病并需要定期用药。

免费客製化服务：

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 技术分析
  • 最终用户分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球自动注射器市场：按类型

  • 可重复使用的
  • 一次性的
  • 客製化
  • 预填充
  • 其他类型

第六章全球自动注射器市场：依处理方式

  • 肿瘤学
  • 气喘
  • 类风湿性关节炎
  • 多发性硬化症
  • 过敏反应
  • 荷尔蒙疗法
  • 糖尿病
  • 偏头痛
  • 其他治疗

第七章全球自动注射器市场：依给药途径

  • 肌肉注射
  • 皮下的

第八章全球自动注射器市场：依技术分类

  • 手动的
  • 弹簧式
  • 电池供电
  • 其他技术

第九章全球自动注射器市场：依最终用户分类

  • 医院和诊所
  • 居家照护环境
  • 门诊就诊环境
  • 其他最终用户

第10章全球自动注射器市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第十一章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十二章 公司简介

  • Pfizer, Inc
  • Eli Lilly and Company
  • AbbVie Inc
  • GlaxoSmithKline plc
  • Mylan NV
  • Johnson & Johnson
  • Sanofi
  • Amgen Inc
  • Merck KGaA
  • Antares Pharma, Inc.
  • Becton, Dickinson, and Company
  • Janssen Global Services, LLC
  • Teva Pharmaceutical
  • Novartis AG
  • Bayer AG
  • SHL Medical
  • Solteam Medical
  • Stevanato Group
  • Boehringer Ingelheim International GmbH
Product Code: SMRC25622

According to Stratistics MRC, the Global Autoinjectors Market is accounted for $111.1 billion in 2023 and is expected to reach $264.6 billion by 2030 growing at a CAGR of 13.2% during the forecast period. Autoinjectors are medical devices designed to deliver a single dose of a particular medication, typically in emergency situations such as severe allergic reactions (anaphylaxis) or other medical emergencies. They are compact, portable, and user-friendly devices that allow individuals to self-administer medication quickly and easily. These devices are commonly used for delivering medications such as epinephrine for allergic reactions, nerve agents' antidotes for military personnel, or medications for certain chronic conditions like multiple sclerosis or rheumatoid arthritis. They play a crucial role in emergency medical care, providing rapid delivery of life-saving medication when time is of the essence.

According to the National Health Interview Survey (NHIS), nearly 52% of the adult population in the US is diagnosed with at least one chronic condition, such as asthma, diabetes, and hypertension.

Market Dynamics:

Driver:

Rising prevalence of chronic diseases

Conditions such as rheumatoid arthritis, multiple sclerosis, and diabetes are becoming more prevalent globally, driving the need for convenient and efficient drug delivery systems. Autoinjectors offer patients a user-friendly solution for self-administration of medications, contributing to their growing popularity in managing chronic conditions. This trend underscores the importance of innovation and accessibility within the healthcare sector to address the evolving needs of patients with chronic diseases.

Restraint:

Stringent regulatory requirements

Meeting stringent regulatory requirements poses significant challenges for companies operating in the market. These requirements encompass various aspects such as safety, efficacy, quality control, and manufacturing standards. Ensuring compliance with regulations set forth by regulatory bodies demands extensive testing, documentation, and adherence to strict guidelines throughout the product lifecycle. Non-compliance can lead to delays in product approval, costly recalls, and damage to the company's reputation.

Opportunity:

Surge in anaphylaxis and severe allergic reactions

There has been a notable surge in anaphylaxis and severe allergic reactions within the autoinjectors market. This increase underscores the critical need for reliable and efficient delivery mechanisms for emergency treatment. Autoinjectors play a vital role in administering life-saving medication swiftly and accurately during such emergencies. As awareness grows and more individuals require access to these devices, the market is witnessing a heightened demand for improved technologies and innovations to address these urgent medical needs.

Threat:

High cost of autoinjectors

The high cost of autoinjectors remains a significant challenge in the market. These devices, crucial for delivering medications such as epinephrine for severe allergic reactions, are often priced prohibitively high, posing financial burdens for patients and healthcare systems. Despite their lifesaving potential, the inflated prices limit accessibility, leading to concerns about equitable healthcare access. Efforts to address this issue include advocating for generic alternatives and increasing transparency in pricing to mitigate the financial strain on patients.

Covid-19 Impact:

The COVID-19 pandemic has significantly impacted the autoinjectors market. Initially, disruptions in the supply chain led to shortages and delays in manufacturing and distribution. However, as the pandemic progressed, there was a surge in demand for autoinjectors due to increased focus on self-administration of medications and the need for remote healthcare. This led to a growing market for autoinjectors, driven by factors such as the rise in chronic diseases and the preference for home healthcare solutions amidst the pandemic's challenges.

The disposable segment is expected to be the largest during the forecast period

The disposable segment is expected to be the largest during the forecast period. These devices offer ease of use and reduced risk of needlestick injuries, enhancing patient compliance and safety. Factors such as increasing prevalence of chronic diseases and expanding applications of biologics drive market expansion. Additionally, advancements in technology and product innovations contribute to market growth.

The diabetes segment is expected to have the highest CAGR during the forecast period

The diabetes segment is expected to have the highest CAGR during the forecast period driven by rising prevalence of diabetes globally and advancements in self-administration technologies. Autoinjectors offer convenience and accuracy in insulin delivery, enhancing patient compliance. Moreover, increasing investments in research and development aimed at improving device efficacy and patient experience are expected to sustain market momentum, fostering innovation and competition among key industry players.

Region with largest share:

North America is projected to hold the largest market share during the forecast period attributed to the rising prevalence of chronic diseases like diabetes and rheumatoid arthritis. Additionally, the increasing adoption of self-administration devices and technological advancements in drug delivery systems are driving market expansion. Furthermore, favorable government initiatives and reimbursement policies support the widespread adoption of autoinjectors across the region, fostering market development.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period. The prevalence of chronic diseases such as diabetes, rheumatoid arthritis, multiple sclerosis, and anaphylaxis is increasing in the region. Regulatory bodies in various countries across the Asia Pacific region are increasingly focusing on ensuring the safety and efficacy of medical devices, including autoinjectors. The aging population in countries is driving the demand for autoinjectors as elderly individuals often require regular medication for chronic conditions.

Key players in the market

Some of the key players in Autoinjectors market include Pfizer, Inc, Eli Lilly and Company, AbbVie Inc, GlaxoSmithKline plc, Mylan N.V., Johnson & Johnson, Sanofi, Amgen Inc, Merck KGaA, Antares Pharma, Inc., Becton, Dickinson, and Company, Janssen Global Services, LLC, Teva Pharmaceutical, Novartis AG, Bayer AG, SHL Medical, Solteam Medical, Stevanato Group and Boehringer Ingelheim International GmbH.

Key Developments:

In May 2023, Boehringer Ingelheim International GmbH announced that the U.S. FDA has approved the Cyltezo Pen, an autoinjector option for Cyltezo (adalimumab), an FDA-approved interchangeable biosimilar to Humira.

In May 2023, SHL Medical and MoonLake Immunotherapeutics collaborated to develop the sonelokimab autoinjector. SHL Medical's Molly autoinjector technology will be utilized for the clinical and potential commercial supply of MoonLake's Nanobody sonelokimab.

Types Covered:

  • Reusable
  • Disposable
  • Customized
  • Prefilled
  • Other Types

Therapies Covered:

  • Oncology
  • Asthma
  • Rheumatoid arthritis
  • Multiple sclerosis
  • Anaphylaxis
  • Hormone therapy
  • Diabetes
  • Migraine
  • Other Therapies

Route of Administrations Covered:

  • Intramuscular
  • Subcutaneous

Technologies Covered:

  • Manual
  • Spring-Loaded
  • Battery-Powered
  • Other Technologies

End Users Covered:

  • Hospital & clinics
  • Homecare settings
  • Ambulatory Care Settings
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Technology Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Autoinjectors Market, By Type

  • 5.1 Introduction
  • 5.2 Reusable
  • 5.3 Disposable
  • 5.4 Customized
  • 5.5 Prefilled
  • 5.6 Other Types

6 Global Autoinjectors Market, By Therapy

  • 6.1 Introduction
  • 6.2 Oncology
  • 6.3 Asthma
  • 6.4 Rheumatoid arthritis
  • 6.5 Multiple sclerosis
  • 6.6 Anaphylaxis
  • 6.7 Hormone therapy
  • 6.8 Diabetes
  • 6.9 Migraine
  • 6.10 Other Therapies

7 Global Autoinjectors Market, By Route of Administration

  • 7.1 Introduction
  • 7.2 Intramuscular
  • 7.3 Subcutaneous

8 Global Autoinjectors Market, By Technology

  • 8.1 Introduction
  • 8.2 Manual
  • 8.3 Spring-Loaded
  • 8.4 Battery-Powered
  • 8.5 Other Technologies

9 Global Autoinjectors Market, By End User

  • 9.1 Introduction
  • 9.2 Hospital & clinics
  • 9.3 Homecare settings
  • 9.4 Ambulatory Care Settings
  • 9.5 Other End Users

10 Global Autoinjectors Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Pfizer, Inc
  • 12.2 Eli Lilly and Company
  • 12.3 AbbVie Inc
  • 12.4 GlaxoSmithKline plc
  • 12.5 Mylan N.V.
  • 12.6 Johnson & Johnson
  • 12.7 Sanofi
  • 12.8 Amgen Inc
  • 12.9 Merck KGaA
  • 12.10 Antares Pharma, Inc.
  • 12.11 Becton, Dickinson, and Company
  • 12.12 Janssen Global Services, LLC
  • 12.13 Teva Pharmaceutical
  • 12.14 Novartis AG
  • 12.15 Bayer AG
  • 12.16 SHL Medical
  • 12.17 Solteam Medical
  • 12.18 Stevanato Group
  • 12.19 Boehringer Ingelheim International GmbH

List of Tables

  • Table 1 Global Autoinjectors Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Autoinjectors Market Outlook, By Type (2021-2030) ($MN)
  • Table 3 Global Autoinjectors Market Outlook, By Reusable (2021-2030) ($MN)
  • Table 4 Global Autoinjectors Market Outlook, By Disposable (2021-2030) ($MN)
  • Table 5 Global Autoinjectors Market Outlook, By Customized (2021-2030) ($MN)
  • Table 6 Global Autoinjectors Market Outlook, By Prefilled (2021-2030) ($MN)
  • Table 7 Global Autoinjectors Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 8 Global Autoinjectors Market Outlook, By Therapy (2021-2030) ($MN)
  • Table 9 Global Autoinjectors Market Outlook, By Oncology (2021-2030) ($MN)
  • Table 10 Global Autoinjectors Market Outlook, By Asthma (2021-2030) ($MN)
  • Table 11 Global Autoinjectors Market Outlook, By Rheumatoid arthritis (2021-2030) ($MN)
  • Table 12 Global Autoinjectors Market Outlook, By Multiple sclerosis (2021-2030) ($MN)
  • Table 13 Global Autoinjectors Market Outlook, By Anaphylaxis (2021-2030) ($MN)
  • Table 14 Global Autoinjectors Market Outlook, By Hormone therapy (2021-2030) ($MN)
  • Table 15 Global Autoinjectors Market Outlook, By Diabetes (2021-2030) ($MN)
  • Table 16 Global Autoinjectors Market Outlook, By Migraine (2021-2030) ($MN)
  • Table 17 Global Autoinjectors Market Outlook, By Other Therapies (2021-2030) ($MN)
  • Table 18 Global Autoinjectors Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 19 Global Autoinjectors Market Outlook, By Intramuscular (2021-2030) ($MN)
  • Table 20 Global Autoinjectors Market Outlook, By Subcutaneous (2021-2030) ($MN)
  • Table 21 Global Autoinjectors Market Outlook, By Technology (2021-2030) ($MN)
  • Table 22 Global Autoinjectors Market Outlook, By Manual (2021-2030) ($MN)
  • Table 23 Global Autoinjectors Market Outlook, By Spring-Loaded (2021-2030) ($MN)
  • Table 24 Global Autoinjectors Market Outlook, By Battery-Powered (2021-2030) ($MN)
  • Table 25 Global Autoinjectors Market Outlook, By Other Technologies (2021-2030) ($MN)
  • Table 26 Global Autoinjectors Market Outlook, By End User (2021-2030) ($MN)
  • Table 27 Global Autoinjectors Market Outlook, By Hospital & clinics (2021-2030) ($MN)
  • Table 28 Global Autoinjectors Market Outlook, By Homecare settings (2021-2030) ($MN)
  • Table 29 Global Autoinjectors Market Outlook, By Ambulatory Care Settings (2021-2030) ($MN)
  • Table 30 Global Autoinjectors Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.